<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410148</url>
  </required_header>
  <id_info>
    <org_study_id>aICP Ophtha</org_study_id>
    <nct_id>NCT02410148</nct_id>
  </id_info>
  <brief_title>aICP in Glaucoma and Papilledema</brief_title>
  <acronym>aICP Ophtha</acronym>
  <official_title>Non-invasive Absolute Intracranial Pressure (ICP) Measurement in Patients With Open-angle Glaucoma and Papilledema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Aarau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Aarau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma remains a disease with an unclear and complex underlying pathophysiology. Recently,&#xD;
      researchers have emphasized not only intraocular pressure (IOP) or vascular dysregulation,&#xD;
      but also translaminar pressure's (TPG) role in glaucoma (TPG=IOP-ICP). A higher TPG may lead&#xD;
      to abnormal function and optic nerve damage due to changes in axonal transportation,&#xD;
      deformation of the lamina cribrosa, altered blood flow, or a combination thereof leading to&#xD;
      glaucomatous damage. However only invasive ICP measurements are available within the&#xD;
      contemporary medicine. The ideas for non-invasive ICP measurement have been approached since&#xD;
      about 1980. Most of the proposed technologies were based on ultrasound and were capable of&#xD;
      monitoring blood flow in intracranial or intraocular vessels, cranium diameter, or acoustic&#xD;
      properties of the cranium. Broad research has extended into sonography of optic nerve sheath&#xD;
      and its relation with elevated ICP. However, most of these correlation-based methods had the&#xD;
      same problem-the need of individual patient specific calibration. Seeking to measure absolute&#xD;
      ICP values, researchers from Kaunas University of Technology created a non-invasive method,&#xD;
      which does not need a patient specific calibration. The method is based on direct comparison&#xD;
      of ICP value with the value of pressure Pe that is externally applied to the tissues&#xD;
      surrounding the eyeball. Intracranial segment of ophthalmic artery (OA) is used as a natural&#xD;
      sensor of ICP and extracranial segment of OA is used as a sensor of Pe. The special two depth&#xD;
      transcranial Doppler (TCD) device is used as a pressure balance indicator when ICP = Pe.&#xD;
&#xD;
      The aim of our study is to assess TPG in patients with primary open open-angle glaucoma&#xD;
      (POAG). In addition the investigators want to measure ICP in patients with papilledema (PE)&#xD;
      in order to compare them with glaucoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is a progressive optic neuropathy leading to the retinal ganglion cell death and&#xD;
      typical optic nerve head (ONH) damage [1]. It remains a disease with an unclear and complex&#xD;
      underlying pathophysiology. Intraocular pressure (IOP) is the main and only modifiable risk&#xD;
      factor for glaucoma [2]. Although lowering IOP helps to decelerate or stabilize the disease,&#xD;
      a vast number of patients still show signs of glaucoma despite an IOP within normal range.&#xD;
      Clearly other pathogenetic mechanisms beyond IOP are involved in the pathogenesis of glaucoma&#xD;
      for certain individuals. Non-IOP factors such as lower systolic ocular perfusion pressure&#xD;
      (OPP), reduced ocular blood flow, cardiovascular disease, and low systolic blood pressure&#xD;
      (BP) have been identified as risk factors for primary open-open-angle glaucoma (POAG) [3-6].&#xD;
      Evidence shows that non-IOP factors can impact the apoptotic process associated with glaucoma&#xD;
      [7].&#xD;
&#xD;
      Recently, researchers have emphasized not only IOP or vascular dysregulation, but also&#xD;
      intracranial pressure's (ICP) role in glaucoma [8-10]. The optic nerve is exposed not only to&#xD;
      IOP in the eye, but also to ICP as it is surrounded by cerebrospinal fluid (CSF) in the&#xD;
      subarachnoid space. Because the lamina cribrosa separates these two pressurized regions [11],&#xD;
      the decrease in pressure that occurs across the lamina cribrosa (IOP-ICP) is known as the&#xD;
      translaminar pressure gradient (TPG). A higher TPG may lead to abnormal function and optic&#xD;
      nerve damage due to changes in axonal transportation, deformation of the lamina cribrosa,&#xD;
      altered blood flow, or a combination thereof leading to glaucomatous damage. Besides, TPG may&#xD;
      be the primarily pressure-related parameter for glaucoma [12-15], since the ONH is located at&#xD;
      the junction between the intraocular space and the orbital retrobulbar space.&#xD;
&#xD;
      However, the role of TPG still remains unknown, because only invasive ICP measurements are&#xD;
      available within the contemporary medicine (lumbar puncture or punction of brain&#xD;
      ventricles-for patients with severe brain injury). The ideas for noninvasive ICP measurement&#xD;
      have been appearing since about 1980. Numerous methods for finding the objects or&#xD;
      physiological characteristics of cerebrospinal system that would be related to the ICP and&#xD;
      its monitoring have been sought by many authors. Most of the proposed technologies were based&#xD;
      on ultrasound and were capable of monitoring blood flow in intracranial or intraocular&#xD;
      vessels, cranium diameter, or acoustic properties of the cranium [16]. Broad research has&#xD;
      extended into sonography of optic nerve sheath and its relation with elevated ICP [17].&#xD;
      However, most of these correlation-based methods had the same problem-the need of individual&#xD;
      patient specific calibration. Seeking to measure absolute ICP values, researchers from Kaunas&#xD;
      University of Technology created a noninvasive method, which does not need a patient specific&#xD;
      calibration [18, 19]. The method is based on direct comparison of ICP value with the value of&#xD;
      pressure Pe that is externally applied to the tissues surrounding the eyeball. Intracranial&#xD;
      segment of ophthalmic artery (OA) is used as a natural sensor of ICP and extracranial segment&#xD;
      of OA is used as a sensor of Pe. A special two depth transcranial Doppler (TCD) device [18,&#xD;
      19] is used as a pressure balance indicator when ICP = Pe. Accuracy, precision, sensitivity,&#xD;
      specificity, and diagnostic value of this method were proven with healthy subjects and&#xD;
      patients with neurological diseases. This device has not yet been used in clinical studies to&#xD;
      investigate TPG significance in glaucoma. The aim of our study is to assess TPG in patients&#xD;
      with primary open open-angle glaucoma (POAG). In addition the investigators want to measure&#xD;
      ICP in patients with papilledema (PE) in order to compare them with glaucoma patients.&#xD;
&#xD;
      The non-invasive ICP measurement using two deeps TCD device allows us to get ICP values from&#xD;
      immediate vicinity of optic nerve, which in turn very important in term of understanding the&#xD;
      pathophysiology of such conditions like PE and POAG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TPG (Translaminar Pressure Gradiant)</measure>
    <time_frame>Day 1</time_frame>
    <description>TPG= (IOP-ICP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial blood pressure</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD (Mean Deviation) in Visual Field</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average RNFL (retinal nerve fiber layer) thickness</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA (best corrected visual acuity)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 14 (+/- 4 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Papilledema</condition>
  <arm_group>
    <arm_group_label>Papilledema</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-invasive aICP measurement in patientes with papilledema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open angle glaucoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-invasive aICP measurement in patients with glaucoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive ICP measurement (Vittamed 305)</intervention_name>
    <description>The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).</description>
    <arm_group_label>Papilledema</arm_group_label>
    <arm_group_label>open angle glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with diagnosed POAG or PE&#xD;
&#xD;
          -  Age: â‰¥18 years at admission&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with wounds, scars including the front orbital region.&#xD;
&#xD;
          -  Intraocular pressure range bellow 12 or above 25 mmHg&#xD;
&#xD;
             &gt; As the aim of the study is to analyze the role of TPG in the progression of POAG and&#xD;
             PE, the study focusses on patients with normal IOP (12-25 mmHg)&#xD;
&#xD;
          -  Patients with any known ocular condition that - according to an Ophthalmologist - may&#xD;
             be worsened by sustained eye pressure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanspeter Killer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Kantonsspital Aarau, Aarau, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asan Kochkorov, MD</last_name>
    <phone>0041 62 838 92 03</phone>
    <email>asan.kochkorov@ksa.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>NeuroReserachOffice</last_name>
    <phone>0041 62 838 92 03</phone>
    <email>nro@ksa.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asan Kochkorov, MD</last_name>
      <phone>+41 62 838 92 03</phone>
      <email>nro@ksa.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Aarau</investigator_affiliation>
    <investigator_full_name>PD Dr.med. HE Killer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>open-angle glaucoma</keyword>
  <keyword>papilledema</keyword>
  <keyword>non-invasive ICP</keyword>
  <keyword>Intracranial pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilledema</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

